+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent Advances in Cancer and Eye Disease Management

  • ID: 4396754
  • Report
  • September 2017
  • Region: Global
  • 15 Pages
  • Frost & Sullivan

This edition of the Genetic Technology TOE depicts life sciences trends across cancer and eye disease management. The corresponding clinical trials scenario is depicted along with industry interactions. A summary of key clinical trials using BMS-986016 therapy is also presented.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Eye disorders, cancer, next-generation cancer immunotherapy, immune checkpoint inhibitors, aldehyde trapping platform, oncoprotein candidate

Note: Product cover images may vary from those shown

Biotechnological Innovations for Cancer and Eye Diseases

  • Next-generation Cancer Immunotherapy
  • Enhancing the Efficacy of Immune Checkpoint Inhibitors
  • Novel Aldehyde Trapping Platform for Eye Disorders
  • Novel Oncoprotein Candidate for Childhood Cancer

Clinical Trial Analysis and Industry Interactions

  • Summary of Key Clinical Trials Using BMS-986016 Therapy
  • Summary of Key Contacts
Note: Product cover images may vary from those shown